Alternative Name: SCHIELD Biodegradable MPT Implant

Description: The SCHIELD implant will be designed for sustained, long-acting delivery of API, capable of dual indication (anti-retroviral plus contraceptive) with zero-order release kinetics. This biodegradable, reversible implant will be subcutaneously placed, discrete, and user-independent to eliminate patient burden.

Product Details

User: Female

Hormonal: Yes

Delivery Method: Subdermal

Duration Type: Long-acting

Duration: 12-18 months

  • single subcutaneous injection every 12 months

Inactive material: Polycaprolactone; GRAS excipient

Multipurpose Preventive Technology (MPT): Yes

Status Details

Developer: RTI International

Project Phase: Pre-Clinical and Clinical Development

Development Stage: Pre-clinical

Began discovery in: 17-Jul

Active Development: Yes

Status Details:
  • This product is still in the early development phase. The API screening and formulations are currently underway, as well as implant fabrication and prototyping.

Additional Information


  • SCHIELD stands for Subcutaneous Contraceptive and HIV Implant Engineered for Long-acting Development.
  • Builds on earlier Capronor implant work, see Capronor entry.

Vertical Tabs